Domenico Giordano

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 135 publications

Real-life effectiveness and safety of bimekizumab in patients with moderate plaque psoriasis: a 54-week multicentre study in the Lazio region.

Real-life effectiveness and safety of bimekizumab in patients with moderate plaque psoriasis: a 54-week multicentre study in the Lazio region.

Journal: Drugs in context

Published: May 06, 2026

Psoriasis in Difficult-to-Treat Areas: A Multicentre, Real-World Retrospective Study Analyzing the Impact of Non-Invasive Imaging Techniques (Dermoscopy, Reflectance Confocal Microscopy and Optical Coherence Tomography) to Monitor the Effectiveness of Risankizumab in the Treatment of Plaque Psoriasis of the Legs.

Psoriasis in Difficult-to-Treat Areas: A Multicentre, Real-World Retrospective Study Analyzing the Impact of Non-Invasive Imaging Techniques (Dermoscopy, Reflectance Confocal Microscopy and Optical Coherence Tomography) to Monitor the Effectiveness of Risankizumab in the Treatment of Plaque Psoriasis of the Legs.

Journal: Clinics and practice

Published: November 19, 2025

Psoriasis severity, comorbidity burden, and biologic therapy: a multicenter observational study using the Charlson Comorbidity Index.

Psoriasis severity, comorbidity burden, and biologic therapy: a multicenter observational study using the Charlson Comorbidity Index.

Journal: The Journal of dermatological treatment

Published: September 24, 2025

Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us?

Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us?

Journal: The Journal of dermatological treatment

Published: June 09, 2025

Real-world analysis of IL-23 inhibitors in patients with moderate-to-severe psoriasis and early musculoskeletal symptoms.

Real-world analysis of IL-23 inhibitors in patients with moderate-to-severe psoriasis and early musculoskeletal symptoms.

Journal: Drugs in context

Published: May 06, 2025

Brodalumab for the treatment of palmoplantar psoriasis.

Brodalumab for the treatment of palmoplantar psoriasis.

Journal: Italian journal of dermatology and venereology

Published: March 19, 2025

Effectiveness of Bimekizumab in Psoriatic Arthritis: A Multicenter Real-Life Study With Clinical and Ultrasound Evaluation in the Lazio Region, Italy.

Effectiveness of Bimekizumab in Psoriatic Arthritis: A Multicenter Real-Life Study With Clinical and Ultrasound Evaluation in the Lazio Region, Italy.

Journal: International journal of dermatology

Published: March 18, 2025

Treating psoriatic arthritis in the early phase: proposal for a shared dermatological and rheumatological therapeutic intervention with biologics and targets synthetic disease-modifying immunosuppressive drugs.

Treating psoriatic arthritis in the early phase: proposal for a shared dermatological and rheumatological therapeutic intervention with biologics and targets synthetic disease-modifying immunosuppressive drugs.

Journal: Italian journal of dermatology and venereology

Published: February 13, 2025

A Rare Cutaneous Tumor With Unusual Dermoscopic Features.

A Rare Cutaneous Tumor With Unusual Dermoscopic Features.

Journal: Clinical case reports

Published: February 07, 2025

Comparing adalimumab biosimilars in the clinical practice of psoriatic patients.

Comparing adalimumab biosimilars in the clinical practice of psoriatic patients.

Journal: Italian journal of dermatology and venereology

Published: February 03, 2025

Effectiveness of Baricitinib in Alopecia Areata Patients With a Current Episode Lasting Longer Than 8 Years: An Italian Multicenter Real-Life Experience in the Lazio Region.

Effectiveness of Baricitinib in Alopecia Areata Patients With a Current Episode Lasting Longer Than 8 Years: An Italian Multicenter Real-Life Experience in the Lazio Region.

Journal: International journal of dermatology

Published: January 26, 2025

Evaluating the Efficacy of Bimekizumab across the Different Sensitive Areas in Moderate-to-Severe Psoriasis: A 52-week Italian Multicenter Real-Life Lazio Experience.

Evaluating the Efficacy of Bimekizumab across the Different Sensitive Areas in Moderate-to-Severe Psoriasis: A 52-week Italian Multicenter Real-Life Lazio Experience.

Journal: Dermatology practical & conceptual

Published: January 14, 2025

Showing 1-12 of 135

Last Updated: 09/26/2026